SCHEMBL10239349

SCHEMBL10239349

Cc1ccc(O)c(NC(=O)C(C)N)c1

nearest known ligand 0.60

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
GAA P10253 8/20 0.60
IDO1 P14902 2/20 0.56
KCNMA1 Q12791 3/20 0.54
SMN1; SMN2 Q16637 3/20 0.53
MAPT P10636 2/20 0.53
NPC1 O15118 4/20 0.52
RAB9A P51151 2/20 0.52
CA12 O43570 1/20 0.52
CA1 P00915 1/20 0.52
CA2 P00918 1/20 0.52
CA9 Q16790 1/20 0.52
TP53 P04637 1/20 0.49
HTT P42858 3/20 0.47
MEN1 O00255 2/20 0.47
KMT2A Q03164 2/20 0.47
POLB P06746 1/20 0.46
MAPK1 P28482 1/20 0.46
PKM P14618 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL14354719 0.86 GAA (0.72) GAAKCNMA1SMN1; SMN2MAPTNPC1
SCHEMBL14354746 0.83 GAA (0.60) GAAKCNMA1SMN1; SMN2MAPTNPC1
SCHEMBL12339799 0.82 GAA (0.58) GAAKCNMA1SMN1; SMN2MAPTNPC1
SCHEMBL12339796 0.82 GAA (0.58) GAAKCNMA1SMN1; SMN2MAPTNPC1
SCHEMBL14354724 0.82 GAA (0.58) GAAKCNMA1SMN1; SMN2MAPTNPC1
SCHEMBL12125130 0.81 GAA (0.57) GAAKCNMA1SMN1; SMN2MAPTNPC1
SCHEMBL4971171 0.81 GAA (0.57) GAAKCNMA1SMN1; SMN2MAPTNPC1
SCHEMBL10239297 0.81 IDO1 (0.54) GAAIDO1KCNMA1SMN1; SMN2CA12
SCHEMBL14354732 0.80 GAA (0.56) GAAKCNMA1SMN1; SMN2MAPTNPC1
SCHEMBL12432821 0.80 GAA (0.56) GAAKCNMA1SMN1; SMN2MAPTNPC1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8501804-B2 Bicyclic compound TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2013-08-06 US disclosed
US-20120010247-A1 BICYCLIC COMPOUND TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120010247-A1 BICYCLIC COMPOUND ACACA, CPT1B, ACACB GAA 1084/4885IDO1 3201/4885KCNMA1 2260/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.